Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14695121 | 0.81 | GAA (0.49) | SMN1; SMN2NPC1RAB9ACYP2C19NPSR1 | |
| SCHEMBL26093211 | 0.78 | HTR2C (0.42) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL15000800 | 0.77 | HTR2C (0.50) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL4388005 | 0.76 | HTR2C (0.46) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL13490134 | 0.75 | HTR2C (0.58) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2579734 | 0.75 | HTR2C (0.58) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2787453 | 0.75 | HTR2C (0.58) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL10797345 | 0.75 | ALDH1A1 (0.53) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL1532832 | 0.75 | HTR2C (0.48) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL1821598 | 0.74 | SMN1; SMN2 (0.65) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569690-B2 | Process for producing oxycarbonyl-substituted piperazine derivative | TORAY FINE CHEMICALS CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20060161003-A1 | Process for producing oxycarbonyl-substituted piperazine derivative | TORAY FINE CHEMICALS CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1548010-A1 | PROCESS FOR PRODUCING OXYCARBONYL-SUBSTITUTED PIPERAZINE DERIVATIVE | Toray Fine Chemicals Co., Ltd. (JP) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060161003-A1 | Process for producing oxycarbonyl-substituted piperazine derivative | DHPS, AQP4, OGFOD1 | HTR2C 1230/4885SMN1; SMN2 3473/4885NPC1 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.